Answers are grounded in this paper and cite their sources.
To evaluate the long-term safety and efficacy of enavogliflozin 0.3 mg/day added to metformin in patients with type 2 diabetes mellitus.
No takes yet. Share an insight, caveat, or question.
Sohn et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: